logo

Seung-Kook Park is a highly accomplished specialist in biopharmaceutical development, boasting years of invaluable R&D experience. He served as the Director at the R&D center of Daewoong Pharmaceutical from 2002 to 2007, where he played a pivotal role in the successful development of Easyef topical solution. This achievement marked a significant milestone as the first new biologic drug to be developed in Korea. Since 2007, Park has been instrumental in leading the overall R&D efforts as the Director of the Bio R&D center at HanAll. His exceptional contributions were duly recognized, leading to his appointment as President of HanAll in 2013. Notably, Park demonstrated his leadership prowess by spearheading a successful licensing deal for 'HL161', an antibody designed to treat autoimmune diseases in 2017. This accomplishment has now become one of the major pipelines of HanAll.

Sean started his biopharma industry career in 2002 as medical advisor at Organon Korea and has taken uniquely diverse leadership positions at Novartis and UCB in Switzerland, Japan and Korea in clinical development, portfolio strategy, and commercial operations in neuroscience, respiratory, endocrinology and infectious disease therapeutic areas. Prior to joining pharma industry, Sean worked as a management consultant at Bain and Co. and a primary care physician in Korea.

Sean currently serves as President and a co-CEO at HanAll, focusing on global R&D. He also serves as a member of board at Daewoong Investment.

Sean graduated from Yonsei University with MD degree and MIT Sloan School of Management with MBA degree.

Su-jin Park is an experienced executive with a proven track record of driving growth and delivering results in pharmaceutical sales and marketing for over 20 years. Most recently, he served as the head of the prescription drug (ETC) marketing and sales division at Daewoong Pharmaceutical. In this role, he provided strategic vision and oversight to drive sales for key products, leading to a record-high ETC sales in the company’s history in 2022 with the successful launch of Fexuclue, a medication for gastroesophageal reflux disease.

Currently, Su-jin serves as a co-CEO at HanAll, overseeing business operations in the Korean office encompassing functions spanning manufacturing, marketing, and sales.

Hyeakyung Ahn is an accomplished professional with a Bachelor's degree in Biology from Chung-Ang University and a Master's degree in Biology from Seoul National University, College of Natural Science. With an impressive career in R&D particularly in biopharmaceutical research, Ahn made significant contributions during her tenure at Daewoong Pharmaceutical. Her expertise and achievements have been vital to the development of innovative solutions and novel therapeutics. Since joining HanAll in 2010, Ahn has continued to lead the company's R&D efforts, playing a crucial role in the development of groundbreaking medicines.

Almira (Ellie) Chabi, MD, EGMP is a physician-scientist and executive who is serving as Chief Medical Officer and Chief Development Officer at HanAll. She leads programs across multiple therapeutic areas including oncology, immunology, neurology and ophthalmology. Dr. Chabi previously held the position of Vice President and Global Therapeutic Area Head for Glaucoma & Neuroprotection as well as Lead for Artificial Intelligence Programs at Santen. Prior to joining Santen, she worked at Genentech in late stage ophthalmology including a senior role on a pivotal Phase III program encompassing over 20 countries. Dr. Chabi began her pharmaceutical career at Merck in the Neuroscience & Ophthalmology Clinical Research Group, working on a range of projects within Ophthalmology as well as Neuroscience leading to multiple successful NDA filings. In addition to deep expertise in drug discovery and development, as well as biomarker and device development, she has been extensively involved in due diligences for business development and venture capital teams. She has also served as a board representative for multiple companies. Dr. Chabi received her undergraduate and medical school education at the University of Wisconsin. In addition to residency training in ophthalmology and surgical fellowship training in Cornea & External Disease, she completed an ophthalmology research fellowship at Cornell University, and has served as adjunct clinical staff at Wills Eye Hospital and Stanford University. Dr. Chabi completed the Bioentrepreneurship program at the University of California-San Francisco and is also an alumna of Wharton Business School’s Management Program.

David has more than 24 years of experience in clinical operations and clinical development spanning academia, biotech and multinational pharmaceutical companies. Prior to joining HanAll, he served at Merck KGaA, Merck Biopharma, as Head of Clinical Operations Japan as well as a stint as Head of Clinical Operations China, contributing to several NDA approvals in Japan and China for multiple oncology drugs. Earlier in his career, David led global clinical trial programs in neuroscience at Sunovion/Dainippon Sumitomo Pharma, leading to approvals in the US and Japan for a blockbuster drug treating schizophrenia and bipolar depression. David holds a B.A. in Neuroscience and Behavior from Columbia University.

Chris is an operationally focused leader with over 25 years of expertise in legal and business development roles within large pharmaceutical companies and small, emerging biotechnology firms. Spanning annual revenues from $50 million to $50 billion, he has overseen more than $20 billion in strategic transactions, including transformative M&A, integration efforts, asset acquisitions, and divestitures aimed at driving growth, ensuring regulatory compliance, and optimizing the company's market position across R&D, commercial operations, and investor relations functions. Chris joins HanAll from Coherus BioSciences, where he served as Chief Business and Legal Officer and led its $65M all-stock acquisition of Surface Oncology and a groundbreaking biosimilars partnership with Cost Plus Drugs. Previously, Chris held leadership positions at Pharmacosmos Therapeutics, Prometheus Biosciences, Takeda, and Pfizer.

Chris holds a JD from Washington University in St. Louis, an MS in Biochemistry and Molecular Biology from Thomas Jefferson University and a BS in Biochemistry from the State University of New York at Stony Brook.